Analyst Price Targets — ATRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 13, 2026 6:37 pm | — | New Street | $6.00 | $4.42 | TheFly | Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) |
| December 19, 2025 11:28 am | — | Canaccord Genuity | $25.00 | $17.23 | TheFly | Atara Biotherapeutics price target raised to $25 from $17 at Canaccord |
| November 13, 2024 2:10 pm | Benjamin Burnett | Stifel Nicolaus | $10.00 | $7.58 | StreetInsider | Atara Biotherapeutics (ATRA) PT Raised to $10 at Stifel |
| August 16, 2024 8:55 am | Salim Syed | Mizuho Securities | $18.00 | $6.83 | TheFly | Mizuho upgrades Atara to Buy into potentially better 2025 |
| August 9, 2022 8:38 am | — | Goldman Sachs | $3.00 | $3.87 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $3 |
| May 24, 2022 7:31 am | — | Goldman Sachs | $4.00 | $4.85 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $4 |
Latest News for ATRA
NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”), of the important May 22, 2026 lead plaintiff deadline.
NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"), of the important May 22, 2026 lead plaintiff deadline.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Atara between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click…
NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including…
New York, New York--(Newsfile Corp. - April 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"), of the important May 22, 2026 lead plaintiff deadline. SO WHAT: If you purchased Atara securities during the Class Period you may be entitled to…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRA.
U.S. House Trading
No House trades found for ATRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.